These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2621826)

  • 1. [Clinical significance of serum calcitonin analysis in endocrine tests of the thyroid-parathyroid system].
    Miki T; Morii H
    Nihon Rinsho; 1989 Dec; 48 Suppl():1097-100. PubMed ID: 2621826
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcitonin as a tumor marker. Use of the radioimmunoassay for calcitonin in the postoperative evaluation of patients with medullary thyroid carcinoma.
    Goltzman D; Potts JT; Ridgway RC; Maloof F
    N Engl J Med; 1974 May; 290(19):1035-9. PubMed ID: 4207025
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical significance of serum thyroglobulin analysis in endocrine tests of the thyroid-parathyroid system].
    Nishikawa M; Inada M
    Nihon Rinsho; 1989 Dec; 48 Suppl():1104-6. PubMed ID: 2695666
    [No Abstract]   [Full Text] [Related]  

  • 4. [Calcitonin, procalcitonin].
    Nagasaki T; Inaba M
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():295-9. PubMed ID: 16149513
    [No Abstract]   [Full Text] [Related]  

  • 5. [Calcitonin and its significance for the diagnosis of medullary carcinoma of the thyroid].
    Gautvik KM
    Tidsskr Nor Laegeforen; 1973 May; 93(15):1143-8. PubMed ID: 4584540
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical significance of serum calcitonin gene related peptide analysis in endocrine tests of the thyroid-parathyroid system].
    Horie H; Takami H
    Nihon Rinsho; 1989 Dec; 48 Suppl():1101-3. PubMed ID: 2621827
    [No Abstract]   [Full Text] [Related]  

  • 7. [The setting up of human serum calcitonin radioimmunoassay and its clinical application].
    Zhan Z; Meng X; Chen L; Zhou X; Liu S
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Jun; 19(3):236-40. PubMed ID: 10453498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial nonmultiple endocrine neoplasia medullary thyroid carcinoma: an evolving clinical entity.
    McHenry CR; Oppenheim DS; Murphy T; Broughan T; Vogt D; Goldfarb WB
    Surgery; 1992 Oct; 112(4):728-32; discussion 732-3. PubMed ID: 1411944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of calcitonin and carcinoembryonic antigen doubling times in medullary thyroid carcinoma.
    Jackson CE; Norum RA; Talpos GB; Feldkamp CS; Tashjian AH
    Henry Ford Hosp Med J; 1987; 35(2-3):120-1. PubMed ID: 2891643
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum calcitonin in thyroid disorders and in pheochromocytoma kindred.
    Hornicek FJ; Danowski TS; Robinson SM; Sweeney KT; Malinin GI
    Ann Clin Lab Sci; 1986; 16(2):103-7. PubMed ID: 3963731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medullary thyroid carcinoma: report of two cases, clinicopathological aspects and its management. Serum calcitonin determination is diagnostic.
    Angeles FS; Catanzaro FP; DiSimone AA
    R I Med J (1976); 1977 Jun; 60(6):289-92, 321. PubMed ID: 267285
    [No Abstract]   [Full Text] [Related]  

  • 12. Calcitonin gene-related peptide as a tumor marker for medullary thyroid carcinoma.
    Takami H; Ito K
    Int Surg; 1992; 77(3):181-5. PubMed ID: 1399365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative pentagastrin-stimulated serum calcitonin concentrations in patients with medullary thyroid carcinoma: reoperations in patients with concentrations bordering the detection limit.
    Meybier H; Schmidt-Gayk H; Buhr H; Raue F
    Henry Ford Hosp Med J; 1989; 37(3-4):138-40. PubMed ID: 2576947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic disorders involving parathyroid hormone and calcitonin.
    Aurbach GD
    Birth Defects Orig Artic Ser; 1971 May; 7(6):48-54. PubMed ID: 4155962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up.
    Weightman DR; Mallick UK; Fenwick JD; Perros P
    Cancer; 2003 Jul; 98(1):41-7. PubMed ID: 12833453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitive calcitonin measurement by two-site immunometric assays: implications for calcitonin screening in nodular thyroid disease.
    Saller B; Görges R; Reinhardt W; Haupt K; Janssen OE; Mann K
    Clin Lab; 2002; 48(3-4):191-200. PubMed ID: 11934221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of calcitonin level in the diagnosis and evaluation of the results of the treatment of medullary carcinoma of the thyroid gland].
    Krassowski J; Słowińska-Srzednicka J; Gietka M; Sawicki A; Kokot F; Zgliczyński S
    Pol Tyg Lek; 1989 Aug 7-14; 44(32-33):757-9. PubMed ID: 2641802
    [No Abstract]   [Full Text] [Related]  

  • 18. Combining provocative agents of calcitonin to detect medullary carcinoma of the thyroid.
    Sisson JC; Gross MD; Frietas JE; Jackson CE; England BG
    Henry Ford Hosp Med J; 1981; 29(2):75-80. PubMed ID: 7263287
    [No Abstract]   [Full Text] [Related]  

  • 19. [Radioimmunological determination of calcitonin in monitoring medullary carcinoma of the thyroid].
    Trucchi M; Marchisio M; Roncallo F; Schenone F; Santaniello B
    Arch Maragliano Patol Clin; 1980; 36():25-30. PubMed ID: 6896418
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experience with presymptomatic screening of patients with C cell carcinoma of the thyroid gland].
    Frilling A; Röher HD; Ponder BA; Goretzki PE; Schlaghecke R; Reiners C
    Chirurg; 1993 Jan; 64(1):28-35. PubMed ID: 8094664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.